Translating the Science of ADCs for Patients with Cancer 

Informed patients are empowered patients. Which is why helping people with cancer understand their disease, as well as how available treatment options might work for them, is a critical focus of our patient advocacy efforts.

Business development is the craft of making connections. Whether with other companies or within our organization, we need to build those bonds that allow us to be successful. 

Cancer research and development is a dynamic and ever-evolving field. One significant area of focus is the role of HER2.

The Galien Foundation has recognized Daiichi Sankyo’s HER2 directed antibody drug conjugate (ADC) with the prestigious 2024 Prix Galien USA Award for Best Biotechnology Product.

For cancer patients, the science concerning their disease is sometimes outside of reach. As a patient-centric organization, we are on a mission to break down those barriers.

Cancer remains one of the most challenging diseases in the world today, but critical advances in science are transforming options for more personalized treatment.

A career of building hope for people with cancer began with a single childhood moment for our Vice President, Global Team Leader, Oncology Research & Development, Dalila Sellami, MD.

As a teenager volunteering at a hospital, Simon King, Chief People Officer at Daiichi Sankyo, Inc., learned the difference between listening with his ears and listening with his heart.

Daiichi Sankyo supports “No One Missed” campaign to build awareness, empower patients and break down barriers to this essential step in cancer care.

As a champion of continuous learning, John Ruggiero, Ph.D., leverages the power of diverse voices to create better tomorrows for patients.

In Japanese, the word for home is uchi, うち. For Gerold Meinhardt, M.D., Ph.D., a German native living in the U.S., his true uchi is Japan.

After suffering a traumatic brain injury in a motor vehicle accident more than 15 years ago, Barbara Tantillo was challenged to redefine what success looks like as a person living with a non-apparent disability.

Ken Keller, President & CEO, Daiichi Sankyo, Inc., and Global Head of Oncology Business on the adventure of a lifetime and how each new one shapes who he is.

Dalal Nesheiwat discusses her PharmD experience and the role of family and mentorship in her pursuit of a fulfilling career.

Michael Grosso talks open heart surgery, Specialty Medicine, and Astronomy

When one combines their passion for science with the ability to address human suffering, “amazing things” can happen, according to Dale Shuster, Senior Vice President, Global Head of Precision Medicine at Daiichi Sankyo.

Fay Dunbar, our Director of Inclusion & Diversity, sat down with Ricki Fairley to discuss an important topic—advocating for Black women living with breast cancer.

At Daiichi Sankyo, we believe that protecting the well-being of survivors during and after their cancer therapy is just as important as delivering innovative medicines to treat their disease.

Neil Albuja, a Senior Director in Finance, shares how military service has shaped his approach to inclusion and diversity.

In partnership with the Ernest Mario School of Pharmacy at Rutgers University, Daiichi Sankyo's PharmD fellowship program provides hands-on experience and exposure to the pharmaceutical industry

At Daiichi Sankyo, Inc., we aim to create essential medicine for longer, better lives. The core and catalyst behind our oncology development plan is our DXd ADC Technology. ADCs, or antibody drug conjugates, are therapies that combine 3 components—an antibody connected to a payload via a linker.

Daiichi Sankyo employee, Eduardo Tozzi, shares his personal story about how he surrounds himself with love each day.

Our Leaders of Innovation: Mark Rutstein, MD, Senior Vice President, Global Head Oncology Clinical Development

CDx leaders born in different corners of the world share their perspectives

What might look like an ordinary wreath displayed at our U.S. headquarters is a powerful symbol of our collective hope and united purpose—to serve patients with compassion.

As a physician and drug developer, Marielle Cohard-Radice, MD has experienced many challenging opportunities throughout her career that have informed her agile approach to leading during times of change.

Daiichi Sankyo and Sarah Cannon Research Institute (SCRI) announced a strategic collaboration with a goal to work together to accelerate the development of new medicines to improve the standard of care for patients with cancer.

Fay Dunbar, Director of Inclusion & Diversity shares what led her to this work and her vision for an equitable workplace

Partnering with the Oncology Community for Progress

Our Leaders of Innovation: Ken Takeshita, MD

Michele Schmidt, RN, has held in her 20-year plus career in oncology drug development bringing new and innovative medicines to patients

Thanks to our veterans contributing to Daiichi Sankyo’s global mission— to contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs.

Prior to his career in drug development, Eric Richards, MS, MPH spent a decade training as a ‘triple threat’ in the performing arts -- acting, singing, and dancing – before specializing in classical vocal music.

Our dedicated advocacy partners are hard at work developing solutions and providing resources to help these patients, and at Daiichi Sankyo, we share their commitment.

At Daiichi Sankyo, we are invested in addressing complex challenges across the clinical trial process.

Our 2022 internship class shares experiences, lessons learned and motivations for a future in healthcare after a summer with Daiichi Sankyo

At Daiichi Sankyo, we believe compassion grows from understanding that no two people suffering from a condition are alike. Each cancer patient has their own set of experiences, challenges and perspectives — a unique story to tell.

During Pride Month, Daiichi Sankyo commemorates the progress that has been made for equal justice under the law for the LGTBQ+ community, while acknowledging that there is more work to be done to raise awareness and encourage inclusiveness.

For Daiichi Sankyo, ASCO22 was historic as we demonstrated our bold leadership in oncology with numerous advances across our ADC portfolio.

At Daiichi Sankyo we proudly observe Asian Pacific American Heritage Month (APAHM) in May. During this month, we recognize our own Asian heritage—Daiichi Sankyo is a global company based in Japan with more than 100 years of history in medical science.

Each spring, we’re tickled pink about the role one of our first leaders played in bringing Japanese cherry trees to the U.S. Capital over 110 years ago.

Lauren and Jennifer are among the 50 mentees who participated in the inaugural year of the Daiichi Sankyo, Inc. Women’s Forum Mentorship Program.

This Rare Disease Day, we hope you will join us in supporting the millions of people across the rare disease community by raising awareness of the resources, programs and support available at rarediseaseday.org.

This February 4, it’s critical for everyone around the globe to come together for World Cancer Day to raise awareness, improve education and spur action around inequities in cancer care.

As we prepare to celebrate the birthday of Dr. Martin Luther King, Jr., we are taking time to reflect on his life and legacy as a man who sowed the seeds of healing in America.

Approximately every three minutes, one person in the U.S. is diagnosed with blood cancer. September is Blood Cancer Awareness Month, a time to show our support for these patients and raise awareness of ongoing research to help fight the disease.